Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis

Susanna J. Lake,1,2,3 John M. Kaldor,4 Myra Hardy,1,2,3 Daniel Engelman,1,2,3 Andrew C. Steer,1,2,3 and Lucia Romani1,4

1Tropical Diseases Research Group, Murdoch Children’s Research Institute, Melbourne, Australia; 2Department of Paediatrics, University of Melbourne, Melbourne, Australia; 3Melbourne Children’s Global Health, Melbourne, Australia; and 4Kirby Institute, University of New South Wales, Sydney, Australia

Background. Scabies is a neglected tropical disease of the skin that can lead to impetigo, serious secondary bacterial infections and immune-mediated diseases. Mass drug administration (MDA) has been reported in several studies to reduce the prevalence of scabies and impetigo. We aimed to assess the efficacy of MDA for scabies on scabies and impetigo.

Methods. We conducted a systematic review and meta-analysis of reports on the impact of MDA on scabies and impetigo. We included randomized control trials and observational evaluations reported from January 1970 to April 2021 and involving human participants. We searched PubMed, Ovid Medline, Embase, and Cochrane. We considered MDA as treatment intended for the whole population, regardless of individual infection status or symptoms. The main outcome assessed was the change in scabies and impetigo prevalence following MDA. This review is registered with PROSPERO (CRD42020169839).

Results. We identified 1110 records, of which 11 met inclusion criteria for the review and 9 were deemed suitable for meta-analysis for scabies and 4 for impetigo. Most studies were in small populations. There was a high degree of heterogeneity between studies (I² value 96.19%). The overall relative reduction of the impact of MDA on scabies prevalence was 79%. The effect size was comparable for MDA based on ivermectin and permethrin. MDA for scabies also led to a reduction in impetigo prevalence with a relative reduction of 66%.

Conclusions. MDA for scabies is highly effective in reducing the prevalence of scabies and impetigo. Further research is needed to determine the durability of impact, and the effectiveness of MDA regimens in larger populations.

Keywords. scabies; impetigo; mass drug administration; ivermectin; permethrin.

Scabies is a skin disease caused by infestation with the mite Sarcoptes scabiei var. hominis. The mite burrows under the skin and causes intense itch and a papular rash. Infestation is often complicated by secondary skin infections with bacteria such as Streptococcus pyogenes and Staphylococcus aureus, which can lead to more severe skin infections, invasive disease, and immune-mediated disease [1]. Scabies also impacts quality of life by disrupting sleep, school or work performance, and by causing stigma [2, 3].

There are an estimated 455 million new cases of scabies globally each year [4]. The mite is transmitted by skin-to-skin contact and is more common in crowded settings. Infestations more frequently occur among people living in resource-poor environments, particularly tropical regions, where prevalence of over 20%, and 50% in children, has been reported [5]. Outbreaks have occurred in institutions such as nursing homes, prisons, and schools. The first line scabies treatment in the majority of guidelines is a topical agent, most commonly permethrin 5% cream or benzyl benzoate 25% lotion [6, 7]. Ivermectin, an oral agent, is also recommended as second line treatment [8]. For scabies, it requires administration of a second dose after 7–14 days because, unlike permethrin or benzyl benzoate, it does not kill mite eggs [9]. Guidelines also recommend treatment for household contacts.

In most high-prevalence settings, individual detection and treatment of scabies is not considered feasible on a large scale, so attention has turned to mass drug administration (MDA), a strategy for infectious disease control that involves treatment of everyone in a population, regardless of whether they have the targeted infection [10]. MDA is a crucial tool in the control of a number of globally important neglected tropical diseases (NTDs) including lymphatic filariasis, onchocerciasis, soil-transmitted helminths, and trachoma [11, 12], and has been used for scabies control in high-prevalence settings, under both programmatic and research frameworks [13]. The first World Health Organization expert consultation on scabies recommended MDA where prevalence is >10% [14].

Received 11 October 2021; editorial decision 11 January 2022; published online 28 January 2022.

Correspondence: L. Romani, The Kirby Institute, Level 6, Wallace Wurth Bldg, UNSW Sydney, NSW 2052 Australia (romani@kirby.unsw.edu.au).

Clinical Infectious Diseases® 2022;75(6):959–67
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. https://doi.org/10.1093/cid/ciac042

Mass Drug Administration for the Control of Scabies • CID 2022;75 (15 September) • 959
Investigations of MDA for scabies have been conducted in a range of settings using a variety of treatment regimens. Several also assessed the impact of MDA for scabies on impetigo [5, 15, 16]. The aim of this study is to support the development of public health guidelines by assessing the efficacy of MDA for scabies on scabies and impetigo.

METHODS

We conducted a systematic review and meta-analysis of reports on the impact of MDA for scabies and impetigo. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered with PROSPERO (CRD42020169839).

Search Strategy and Selection Criteria

We searched for randomized controlled trials and observational evaluations of MDA for scabies. We searched Pubmed, Ovid Medline, Embase, and Cochrane from January 1970 to April 2021. We used search terms including “scabies,” “mass-drug-administration,” “preventative-chemotherapy,” “community,” and “population” (full search in Supplementary Materials). We contacted investigators of studies that had been registered but not published and of other studies that we were aware of. We searched gray literature databases, Google Scholar, and reference lists for reports and conference proceedings not published in peer-reviewed journals. No language restrictions were applied.

Study Eligibility

Only human studies were eligible for inclusion. Studies were included if they reported on the prevalence of scabies before and after MDA in the same population, with an agent known to have therapeutic effect against the scabies mite. For the purposes of this review, we consider MDA as treatment intended for the whole population, regardless of individual infection status or symptoms. We included reports of treatment strategies covering at least 80% of the population with an anti-scabies agent. Agents known to have therapeutic activity against scabies include: orally administered ivermectin and topical agents permethrin, benzyl benzoate, lindane, crotamiton, malathion, sulfur and dieldmethrin [7]. Reports of mass treatment used in response to outbreaks in institutional settings, or other closed settings such as refugee camps, were excluded. Studies were excluded if prevalence was not assessed before MDA (baseline) and at least one month after MDA. Studies were eligible for inclusion in meta-analysis if they reported scabies prevalence, across all age groups before and after MDA.

The MDA regimen was considered to be “ivermectin-based” even if medications other than ivermectin were offered to people in whom ivermectin was contraindicated (eg, young children or pregnant women) [17].

Quality Assessment

We used the Cochrane Collaboration’s tool for assessing risk of bias [18]. Studies were assessed independently by two investigators (S.J.L. and L.R.) in multiple domains of bias, including selection, performance, detection, attrition, and reporting. We also assessed the response or participation rate in the study, the quality of the scabies assessment (as described in the study report), and the statistical analysis of the results.

Data Extraction

All titles and abstracts identified were screened for relevance by S.J.L. with referral to L.R. and J.M.K. to resolve queries. Full texts of papers assessed to be relevant were reviewed by S.J.L. and L.R. independently of each other with referral to J.M.K. in the case of discordant opinions. The following variables were extracted: population (including location, years, demographic characteristics), study design (comparison groups, randomization, inclusion and exclusion criteria, sample size), scabies assessment method, intervention (MDA agent, dosing regimen), and outcomes (scabies and impetigo prevalence before and after MDA).

Data Analysis

For each study, we calculated the relative and absolute change in scabies prevalence between the pre-MDA and post-MDA assessments. If multiple time points of assessment were reported post-MDA, we calculated the change for the timepoint closest to 12 months. If a study had multiple arms, we considered them separately for analysis. We examined the change in scabies prevalence visually by plotting prevalence for each study over time. We compared outcomes by agent and dosing regimens as well as longer terms outcomes when reported.

For impetigo, we calculated the relative and absolute change in prevalence between the pre- and post-MDA assessments. We visually compared the change in impetigo prevalence for each study as well as comparing the change in scabies and impetigo prevalence for each study.

We used Stata (version 17.0, StataCorp) to perform the meta-analysis. We used a random effects model to calculate the risk-ratio of the change in scabies and impetigo prevalence between baseline and the primary endpoint of each study. We conducted a sub-analysis on studies where scabies prevalence at baseline was greater than 10% and by agent. We calculated the overall I² [2] statistic to assess heterogeneity of studies.

RESULTS

We identified 1108 records through database searches and an additional two records through other sources (Figure 1). After duplicates were removed, 841 records were screened by title and abstract. A further 811 were excluded leaving 30 full-text manuscripts, which were reviewed for eligibility. Following full-text assessment, a further 19 were excluded, leaving 11 studies, of which
9 were included in the meta-analysis for scabies and 4 for the meta-analysis for impetigo. We excluded 2 studies from the meta-analysis for both scabies and impetigo because only prevalence in children was available at the 12-month time point [19, 20].

Studies were reported from 3 geographic regions with the majority (n = 9) conducted in Pacific Island countries (Figure 2). Approximately 36,000 individuals received MDA specifically for scabies, and a further 2269 received MDA with an antiscabetic for lymphatic filariasis and were assessed for the impact on scabies.

Of the included studies, all but 1 found a decrease in scabies prevalence after MDA (Figure 3). The overall risk-ratio of the change in prevalence following MDA was 0.21 (95% confidence interval [CI] .1–.45) indicating that MDA is favored with a relative reduction of 79%. The I² value was 96.19%, indicating a high degree of heterogeneity between studies. There was a greater reduction in scabies prevalence when only studies with a baseline prevalence of more than 10% were included (Supplementary Figure 1). In these studies the overall risk-ratio was 0.15 (95% CI .08–.29) equating to a relative reduction of 85%.

*MDA: Mass drug administration; RCT: Randomised control trial

Figure 1. Study selection. Abbreviations: MDA, mass drug administration; RCT, randomized control trial.

---

961

• CID 2022:75 (15 September) • Mass Drug Administration for the Control of Scabies • CID 2022:75 (15 September) • 961
Of the 11 studies, 8 were designed to assess interventions specifically for scabies. The other three studies investigated the impact of MDA on scabies alongside other diseases including lymphatic filariasis [21], intestinal helminthiases [22], and trachoma [16]. The impact of scabies MDA on impetigo was assessed in 6 studies, and 1 also investigated the impact on hematuria [19]. A range of dosing regimens were used across the studies (Table 1). Ivermectin was the primary MDA agent for 7 studies, 3 used permethrin, and 1 had separate permethrin and ivermectin arms. For participants in whom ivermectin is contraindicated, most

![Figure 2. Map showing the location, agent used, and number of participants of mass drug administration for scabies.](image)

![Table 1. Summary of studies included in the analysis. | Study | Scabies cases | Total participants | Scabies cases | Total participants | Risk ratio with 95% CI | Weight (%) |
|---|---|---|---|---|---|---|
| Taplin 1991 – Panama (Permethrin) | 245 | 756 | 9 | 795 | .03 [.02, .07] | 9.83 |
| Carapetis 1997 – Australia (Permethrin) | 36 | 125 | 8 | 76 | .33 [.16, .68] | 9.70 |
| Bockarie 2000 – PNG (Ivermectin) | 27 | 31 | 8 | 31 | .30 [.16, .55] | 9.92 |
| Heukelbach 2004 – Brazil (Ivermectin) | 21 | 548 | 8 | 535 | .39 [.17, .87] | 9.48 |
| Kearns 2015 – Australia (Ivermectin) | 42 | 1002 | 113 | 1060 | .25 [1.80, 3.59] | 10.37 |
| Romani 2015 – Fiji (Permethrin) | 222 | 532 | 71 | 449 | .38 [.30, .48] | 10.49 |
| Romani 2015 – Fiji (Ivermectin) | 230 | 716 | 11 | 587 | .06 [.03, .11] | 9.96 |
| Marks 2018 – Solomon Islands (Ivermectin) | 135 | 1291 | 9 | 1083 | .08 [.04, .16] | 9.80 |
| Martin 2018 – Tanzania (Ivermectin) | 101 | 2269 | 17 | 2021 | .19 [.11, .31] | 10.12 |
| Romani 2019 – Solomon Islands (Ivermectin) | 261 | 1399 | 29 | 1261 | .12 [.08, .18] | 10.33 |

Overall

Heterogeneity: \(t^2 = 1.44, I^2 = 96.19\%, H^2 = 26.27\)

Test of \(\theta = 0\): \(Q(9) = 262.50, P = .00\)

Test of \(\theta = 0\): \(z = -4.02, P = .00\)

Random-effects REML model

![Figure 3. Forest plot showing the association of scabies prevalence before and after mass drug administration. Abbreviations: CI, confidence interval; MDA, mass drug administration; PNG, Papua New Guinea.](image)
| Country         | N   | Intervention                                                                 | Scabies Assessment Method                                                                 | Endpoint Used | Scabies Endpoint | Post-MDA Prevalence | Relative Reduction | Impetigo Endpoint | Post-MDA Prevalence | Relative Reduction |
|-----------------|-----|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------|------------------|---------------------|-------------------|-------------------|---------------------|-------------------|
| Africa          |     |                                                                              |                                              |               |                  |                     |                   |                   |                    |                   |
| Tanzania [21]   | 2269| Ivermectin 1 dose, 4 years                                                  | Community health workers trained in clinical diagnosis of scabies                          | 12 months     | 4.4%             | 0.8%                | 80.9%             |                   |                    |                   |
| Central/South America |     |                                                                              |                                              |               |                  |                     |                   |                   |                    |                   |
| Brazil [22]     | 576 | Ivermectin 2 doses in parasitic skin disease/intestinal helminths and households | Experienced examiner                                                                        | 9 months      | 3.8%             | 1.5%                | 60.5%             |                   |                    |                   |
| Panama [26]     | 756 | Permethrin 2 doses                                                           | Experienced examiner                                                                        | 12 months     | 33%              | 1.1%                | 96.7%             |                   |                    |                   |
| Pacific         |     |                                                                              |                                              |               |                  |                     |                   |                   |                    |                   |
| Australia [25]  | 1013| Ivermectin 1 dose in non-scabies and scabies                                | Health workers using clinical guidelines                                                    | 12 months     | 4%               | 9%                  | 225% (increase)   |                   |                    |                   |
| Australia [20]  | 2200| Permethrin 1 dose in non-scabies and mild scabies                           | Experienced examiner                                                                        | 7 months      | 35%              | 4.1%                | 88.3%             | 22.5%             | 5.3%               | 76.4%             |
| Australia [29]  | 200-250| Permethrin 1 dose in non-scabies and mild scabies                           | Experienced examiner                                                                        | 10 months     | 28.8%            | 9.5%                | 67%               | 49%               | 23%                | 53.1%             |
| Fiji [5]        | 2051| A. Ivermectin 1 dose in non-scabies                                         | According to clinical guidelines                                                           | 12 months     | A. 32.1%         | A. 1.9%             | A. 94%            | A. 24.6%          | A. 8%              | A. 6.7%            |
|                 |     | B. Permethrin 1 dose in non-scabies                                         |                                                                                             |               | B. 41.7%         | B. 15.8%            | B. 62.1%          | B. 24.6%          | B. 11.4%           | B. 53.7%           |
| PNG [23]        | 31  | Ivermectin 1 dose                                                            | Unclear                                                                                     | 5 months      | 87%              | 26%                 | 70.1%            |                   |                    |                   |
| Solomon Islands [16] |     |                                                                              |                                              |               |                  |                     |                   |                   |                    |                   |
| Solomon Islands [28] | 1291| A. Ivermectin and Azithromycin                                                | Experienced examiner                                                                        | 12 months     | 10.5%            | 0.8%                | 92.4%            | A. 10.1%          | A. 2.5%            | A. 75.2%          |
| Solomon Islands [19] |     |                                                                              |                                              |               |                  |                     |                   |                   |                    |                   |

Abbreviations: MDA, mass drug administration; PNG, Papua New Guinea.
Supplementary Figure 4. A, Scabies prevalence by month following ivermectin-based mass drug administration. B, Scabies prevalence by month following permethrin-based mass drug administration. Abbreviations: MDA, mass drug administration; PNG, Papua New Guinea.
in the meta-analysis (across 4 studies) the overall risk-ratio for impetigo following MDA was 0.34 (0.26–0.43) equating to a relative reduction of 66% (Figure 5).

The SHIFT study in Fiji showed a greater relative reduction in impetigo after ivermectin MDA (67.5%) compared to permethrin MDA (53.7%) [5]. In 2 Solomon Islands studies, azithromycin was simultaneously distributed as MDA, in 1 of the studies, there was a comparison group who received ivermectin only. In this study the relative reduction in impetigo was similar between groups (72.7% compared to 75.2%) [28]. The second study gave all participants both ivermectin and azithromycin MDA and found a relative reduction of 74.2% [16]. A study in Australia demonstrated both a reduction in the severity and prevalence of impetigo, up to 25 months after MDA [29].

**DISCUSSION**

Our review found that MDA for scabies, across a diverse range of study designs and settings, led to substantial reductions in both scabies and impetigo prevalence. There was a relative reduction of 79% in scabies following MDA and 66% in impetigo. In populations with a prevalence of scabies >10%, there was a greater reduction in scabies indicating that MDA may be more effective in this population. The effect size was similar for ivermectin-based and permethrin MDA.

All reported studies used permethrin for the entire treated population, or ivermectin plus a topical agent for people in whom ivermectin is contra-indicated. Although the overall results for ivermectin-based and permethrin MDA were comparable, in the only study where they were directly compared, there was a substantially greater reduction in scabies following ivermectin MDA [24]. As an oral agent, ivermectin offers a number of practical advantages over permethrin, which requires application to the whole body presenting challenges to use as directly observed treatment, so it is difficult to ensure high levels of adherence [30]. It is also more expensive and logistically challenging to transport cream compared to tablets. Permethrin is often used as an alternative agent to ivermectin due to its favorable safety profile in groups where ivermectin is contraindicated and greater patient acceptability due to less side effects compared to other topical agents, particularly benzyl benzoate [19]. Within the 2 broad groups of MDA, there was no clear relationship between the dose regimen and reduction in scabies. No study directly compared the efficacy of one versus two doses.

Most studies of MDA for scabies have been trials in remote settings. The largest population involved was in Solomon Islands, where 26 000 people received treatment [16]. Several large-scale scabies MDA programs have been conducted in Ethiopia, including 1 reaching over 9 million people, but reporting of these programs did not meet inclusion criteria for this review [31–33]. In these programs, communities with a scabies prevalence over 15% received MDA, although those with a prevalence <15% were offered case and contact treatment.

We found that MDA for scabies led to a reduction in the prevalence of impetigo, although not by as great a magnitude as for scabies (Supplementary Figure 5), and in most studies the reduction was sustained over time. The effect of scabies MDA on impetigo is important because of its potential impact on some of the serious downstream complications [34, 35].

Limitations of our review and meta-analysis was the relatively small number of published reports and the heterogeneity of study quality, sample size, and methods. Despite some geographic diversity across tropical regions, there were no studies from Asia, and few from African and Central and South American countries. Caution is required in generalizing findings beyond small island settings to promote MDA as a public health intervention at a larger scale. There is a need for studies in larger populations and in varied settings, including urban areas.

There was a lack of detail on how scabies and impetigo were diagnosed in many studies, and consensus diagnostic criteria were not used, which may have led to biased reporting of

| Study                        | Pre-MDA Impetigo cases | Total participants | Post-MDA Impetigo cases | Total participants | Risk Ratio with 95% CI | Weight (%) |
|------------------------------|------------------------|--------------------|-------------------------|--------------------|------------------------|------------|
| Carapetis 1997 – Australia (Permethrin) | 61                     | 125                | 20                      | 82                 | 0.30 [0.33, 0.76]      | 15.15      |
| Romani 2015 – Fiji (Permethrin)     | 131                    | 532                | 51                      | 449                | 0.46 [0.44, 0.62]      | 19.57      |
| Romani 2015 – Fiji (Ivermectin)    | 176                    | 716                | 47                      | 587                | 0.35 [0.24, 0.44]      | 19.39      |
| Marks 2018 – Solomon Islands (Ivermectin & Azithromycin) | 79                     | 653                | 20                      | 605                | 0.27 [0.17, 0.44]      | 13.41      |
| Marks 2018 – Solomon Islands (Ivermectin & Azithromycin) | 66                     | 638                | 12                      | 478                | 0.24 [0.13, 0.44]      | 10.26      |
| Romani 2019 – Solomon Islands (Ivermectin & Azithromycin) | 347                    | 1399               | 81                      | 1261               | 0.26 [0.21, 0.33]      | 22.22      |

Overall 0.25 0.5

Heterogeneity: $I^2 = 0.06$, $I^2 = 64.10\%$, $H^2 = 2.79$

Test of $\theta = 0$: $Q(5) = 14.46$, $P = .01$

Test of $\theta = 0$: $z = -8.79$, $P = .00$

Random-effects REML model

**Figure 5.** Forest plot showing the association of impetigo prevalence before and after mass drug administration. Abbreviations: CI, confidence interval; MDA, mass drug administration.
prevalence and directly affect the impact assessments of MDA (Table 1). The International Alliance for the Control of Scabies has published diagnostic criteria that have been used in more recent studies to address the need for standardized diagnosis in surveys, trials, and evaluation of programmatic interventions [36].

Although our data support the role of MDA for scabies control, there remain several key questions to be addressed before it can be adopted as a public health intervention more widely. These research gaps include the relative efficacy of alternate dosing regimens, the number and frequency of MDA rounds, cost-effectiveness, and safety and feasibility of integration with MDA drugs for other NTDs [1]. Although some studies documented the long-term effects of MDA it is unclear if multiple annual or biennial rounds would have a further sustained impact. Some studies showed the impact of active case management after MDA [19, 26], however further research is needed to understand the role of surveillance and treatment once prevalence has been reduced by MDA.

Overall, we demonstrated that although there are a limited number of studies there is substantial evidence to show that MDA for scabies can significantly reduce community prevalence of scabies and impetigo, and these effects can be long lasting. The impact of MDA on scabies prevalence is likely to be multifactorial, dependent on the baseline prevalence of scabies, MDA coverage, movement and social dynamics of the population, as well as the agent and dose regimen used. Further research is required to determine what prevalence of scabies should trigger MDA to control the hyperendemicity of scabies within communities, and the MDA regimen that is most clinical and cost effective for extensive roll out.

Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Financial support. D. E., L. R., J. M. K., and A. C. S. are supported by fellowships from the National Health and Medical Research Council of Australia. A. C. S. is also supported by the National Heart Foundation of Australia and the Viertel Charitable Foundation.

Potential conflicts of interest. D. E. reports being Chair for International Alliance for the Control of Scabies, a not-for-profit association, unpaid role. M. H. reports payments to the institution outside of the submitted work from Bill and Melinda Gates Foundation, Coalition for Operational Research on Neglected Tropical Diseases, funded at The Task Force for Global Health primarily by the Bill and Melinda Gates Foundation, by UK aid from the British Government, and by the US Agency for International Development through its Neglected Tropical Diseases Program, and Australian Centre for the Control and Elimination of Neglected Tropical Diseases, National Health Medical Research Council Centre for Research Excellence; and Ackman Travelling Scholarship from the University of Melbourne paid to self. S. L. reports stipend paid to self for Postgraduate Health Research Scholarship—Royal Children’s Hospital Melbourne, Australia outside of the submitted work. A. C. S. reports being Co-Director of the Australian Strep A Vaccine Initiative, funding the Australian Government, Co-Direction of the Streptococcal Global Vaccine Consortium, funding by the Wellcome Trust, grants or contracts from the Australian Government Medical Research Fund, and Welcome Trust outside of the submitted work; participation on a DSMB for studies on moxidectin for scabies—Medicine Development for Global Health (no payments); and President of the Lancefield Society (no payments). All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Engelman D, Cantey PT, Marks M, et al. The public health control of scabies: priorities for research and action. The Lancet 2019; 394:81–92.
2. Van Der Linden N, Van Gool K, Gardner K, et al. A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. PLoS NeglTrop Dis 2019; 13:e0007182.
3. Mitchell E, Bell S, Thean L, et al. Community perspectives on scabies, impetigo and mass drug administration in Fiji: a qualitative study. PLoS NeglTrop Dis 2020; 14:e0008825.
4. Vor T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390:1211–59.
5. Romani L, Steer AC, Whitfield MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis 2015; 15:960–7.
6. eTG complete. Dermatology - Insects and Mites. Melbourne, Victoria: Therapeutic Guidelines Ltd.
7. Hay RI, Steer AC, Engelman D, Walton S. Scabies in the developing world—its prevalence, complications, and management. Clin Microbiol Infect 2012; 18:313–23.
8. WHO. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019.
9. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010; 362:717–25.
10. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357:1018–27.
11. Hotez P. Mass drug administration and integrated control for the world’s high-prevalence neglected tropical diseases. Clin Pharm Therap 2009; 85:659–64.
12. Amato VS, Tuon FF. Mass drug administration for the control of Strongyloides stercoralis infection: progress and challenges. Clin Infect Dis 2020; 71:3229–31.
13. Engelman D, Steer AC. Control strategies for scabies. Trop Med Infect Dis 2018; 3:98.
14. Engelman D, Marks M, Steer AC, et al. A framework for scabies control. PLoS Negl Trop Dis 2021; 15:e0009661.
15. Marks M, Taotao-Wini B, Satorara L, et al. Long term control of scabies fifteen years after an intensive treatment programme. PLoS Negl Trop Dis 2013; 9:e0004246–e.
16. Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis 2019; 19:510–8.
17. Hardy M, Engelman D, Steer A. Scabies: a clinical update. Aust Fam Physician 2017; 46:264–8.
18. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928–d5928.
19. Lawrence G, Leaafasia J, Sheridan J, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin Latte contre la gale, les lesions cutanees et l’ hematurie chez les enfants des iles Salomon: un autre role pour l’ ivermectine: resu. Bull World Health Organ 2005; 83:34–42.
20. Wong LC, Amega B, Connors C, Barker R, Dulla ME, Currie BJ. Outcome of an interventional program for scabies in an Indigenous community. Med J Aust 2001; 175:367–70.
21. Martin D, Wiegand R, Goodhew B, Lammie P, Mkocha H, Kasubi M. Impact of ivermectin mass drug administration for lymphatic filariasis on scabies in eight villages in Kongwa District, Tanzania. Am J Trop Med Hyg 2018; 99:937–9.
22. Heukelbach J Jr, Winter B, Wilcke T, et al. Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population. Traitement de masse selektif par l’ ivermectine contre les helminthiases intestinales et les dermatoses parasitaires dans une population sève 2004; 82:563–71.
23. Bockarie MJ, Alexander NDE, Kazura JW, Bockarie F, Griffin L, Alpers MP. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop 2000; 75:127–30.

24. Romani L, Whitfield MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 2015; 373:2305–13.

25. Kearns TM, Speare R, Cheng AC, et al. Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian aboriginal community. PLoS Negl Trop Dis 2015; 9:e0004151.

26. Taplin D, Meinking TL, Porcelain SL, et al. Community control of scabies: a model based on use of permethrin cream. Lancet 1991; 337: 1016–8.

27. Marks M, Romani L, Sokana O, et al. Prevalence of scabies and impetigo 3 years after mass drug administration with ivermectin and azithromycin. Clin Infect Dis 2020; 70:1591–5.

28. Marks M, Toloka H, Baker C, et al. Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Clin Infect Dis 2019; 68:927–33.

29. Carapetis J, Connors CM, Yarmirr D, Krause VL, Currie BJ. Success of a scabies control program in an Australian aboriginal community. Pediatr Infect Dis J 1997; 16:494–9.

30. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R. Community management of endemic scabies in remote aboriginal communities of Northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis 2009; 3:e444.

31. Enbiale W, Ayalew A, Gebrehiwot T, et al. Does mass drug administration for community-based scabies control work? The experience in Ethiopia. J Infect Dev Ctries 2020; 14:785–855.

32. Enbiale W, Baynie TB, Ayalew A, et al. "Stopping the itch": mass drug administration for scabies outbreak control covered for over nine million people in Ethiopia. J Infect Dev Ctries 2020; 14:285–355.

33. Enbiale W, Ayalew A. Investigation of a scabies outbreak in drought-affected areas in Ethiopia. Trop Med Infect Dis 2018; 3:114.

34. Thornley S, Marshall R, Jarrett P, Sundborn G, Reynolds E, Schofield G. Scabies is strongly associated with acute rheumatic fever in a cohort study of Auckland children. J Paediatr Child Health 2018; 54:625–32.

35. Thean LJ, Jenney A, Engelman D, et al. Prospective surveillance for invasive Staphylococcus aureus and group A Streptococcus infections in a setting with high community burden of scabies and impetigo. Int J Infect Dis 2021; 108:333–9.

36. Engelman D, Yoshizumi J, Hay RJ, et al. The 2020 international alliance for the control of scabies consensus criteria for the diagnosis of scabies. Br J Dermatol 2020; 183:808–20.